Website
Ratings & Metrics
Financial Documents
Entity | Document Type | Tax ID |
---|---|---|
Lupus Research Alliance | IRS Form 990 | 58-2492929 |
Lupus Research Alliance | Audited Consolidated Financial Statements | Multiple |
Entity: Lupus Research Alliance Document Type: IRS Form 990 Tax ID: 58-2492929 |
Entity: Lupus Research Alliance Document Type: Audited Consolidated Financial Statements Tax ID: Multiple |
Governance & Transparency
Top Salaries
Name | Title | Compensation | |
---|---|---|---|
1 | Kenneth M. Farber | President/CEO | $503,095 |
2 | Teodora Staeva | Chief Scientific Officer | $355,838 |
3 | Albert Roy | Executive Director, Lupus Clinical Investigators Network | $337,000 |
1 Name: Kenneth M. Farber Title: President/CEO Compensation: $503,095 |
2 Name: Teodora Staeva Title: Chief Scientific Officer Compensation: $355,838 |
3 Name: Albert Roy Title: Executive Director, Lupus Clinical Investigators Network Compensation: $337,000 |
Analysts' Notes
According to the Lupus Research Alliance consolidated audit of December 31, 2020 (Note 10, Loan Payable): "In April 2020, the Alliance received a $698,800 Paycheck Protection Program (PPP) loan with an interest rate of 1.00% and a maturity of 2 years. The loan and any accrued interest can be forgiven in its entirety if the loan proceeds are applied towards applicable payroll and occupancy costs, as defined by the Coronavirus Aid, Relief and Economic Security Act. The Alliance was informed that the loan was forgiven on June 9, 2021." |
According to the Lupus Research Alliance consolidated audit of December 31, 2020 (Note 1, Organization): "During the year ended December 31, 2020, the Alliance received approximately 72% of its contributions from one foundation and one trust and during the year ended December 31, 2019, approximately 34% of its contributions from one corporation and one trust." |
According to the Lupus Research Alliance consolidated audit of December 31, 2020 (Note 6, Investments), the Alliance reports having total investments with a fair value of $81,150,155 and $62,118,380 at December 31, 2020 and 2019, respectively. "At December 31, 2020 and 2019, approximately 47% and 42%, respectively, of total investments was invested in one Fortune 500 company." |
According to the Lupus Research Alliance consolidated audit of December 31, 2020 (Note 16, Risks and Uncertainties): "In March 2020, the United States declared the global pandemic novel coronavirus COVID-19 outbreak a national emergency. As a result, the Alliance has suspended some of its program activities at the direction of state and local governmental authorities. Management continues to evaluate the potential impact that the resulting economic uncertainties may have on the Alliance and believes that its current financial assets are sufficient to support the Alliance's operations on an ongoing basis." |